307 related articles for article (PubMed ID: 26893445)
1. Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Kubitza D; Berkowitz SD; Misselwitz F
Clin Appl Thromb Hemost; 2016 Jul; 22(5):412-22. PubMed ID: 26893445
[TBL] [Abstract][Full Text] [Related]
2. A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban.
Kreutz R
J Thromb Thrombolysis; 2014; 38(2):137-49. PubMed ID: 24293106
[TBL] [Abstract][Full Text] [Related]
3. Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.
Trujillo T; Dobesh PP
Drugs; 2014 Sep; 74(14):1587-603. PubMed ID: 25178252
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of rivaroxaban: emerging new clinical evidences?
Mont L; Marín F; Dalmau FG; Martínez MS; Cullere JG
Future Cardiol; 2015 Sep; 11(5):565-83. PubMed ID: 26111102
[TBL] [Abstract][Full Text] [Related]
5. Dosing of rivaroxaban by indication: getting the right dose for the patient.
Escolar G; Carne X; Arellano-Rodrigo E
Expert Opin Drug Metab Toxicol; 2015; 11(10):1665-77. PubMed ID: 26329812
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban for the treatment and prevention of thromboembolic disease.
Antoniou S
J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702
[TBL] [Abstract][Full Text] [Related]
7. Dose-finding study of rivaroxaban in hemodialysis patients.
De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.
Tellor KB; Patel S; Armbruster AL; Daly MW
J Clin Pharm Ther; 2015 Aug; 40(4):447-51. PubMed ID: 26010016
[TBL] [Abstract][Full Text] [Related]
9. Management of rivaroxaban in relation to bodyweight and body mass index.
Uprichard J
Ther Adv Cardiovasc Dis; 2016 Oct; 10(5):294-303. PubMed ID: 27090286
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions.
Kvasnicka T; Malikova I; Zenahlikova Z; Kettnerova K; Brzezkova R; Zima T; Ulrych J; Briza J; Netuka I; Kvasnicka J
Curr Drug Metab; 2017; 18(7):636-642. PubMed ID: 28524005
[TBL] [Abstract][Full Text] [Related]
11. Optimal dosing of rivaroxaban is undefined.
Moore TJ
BMJ; 2016 Oct; 355():i5549. PubMed ID: 27756735
[No Abstract] [Full Text] [Related]
12. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
Spencer RJ; Amerena JV
Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
[TBL] [Abstract][Full Text] [Related]
13. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
[TBL] [Abstract][Full Text] [Related]
15. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban: practical considerations for ensuring safety and efficacy.
Smythe MA; Fanikos J; Gulseth MP; Wittkowsky AK; Spinler SA; Dager WE; Nutescu EA
Pharmacotherapy; 2013 Nov; 33(11):1223-45. PubMed ID: 23712587
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
Kreutz R
Fundam Clin Pharmacol; 2012 Feb; 26(1):27-32. PubMed ID: 21848931
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients.
Konicki R; Weiner D; Herbert Patterson J; Gonzalez D; Kashuba A; Cao YC; Gehi AK; Watkins P; Powell JR
Clin Transl Sci; 2020 Jul; 13(4):777-784. PubMed ID: 32267996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
